Top 10 Medical AI Stocks on Wall Street’s Radar

Page 9 of 9

1. Certara Inc. (NASDAQ:CERT)

Number of Hedge Fund Holders: 18

Certara Inc. (NASDAQ:CERT) offers its Model Informed Drug Development (MIDD) biosimulation software and AI-driven services to help pharma and biotech firms speed up the journey of drug research, development, and market approval. The proprietary software and a leading drug development team enable the company’s clients to derisk projects, reduce costs and timelines, and help better understand the impact of new therapies on patients. The company’s Certara.AI platform is used for deploying client-specific generative pre-trained transformers (GPTs) in the life sciences sector.

On January 17th, Leerink Partners boosted the company’s target price to $13 from $12 and reiterated its “Hold” rating. Analyst Michael Cherny’s rating is based on Certara Inc.’s (NASDAQ:CERT) robust FY24 performance, driven by revenue growth in both software and services segments, attributable to the Chemaxon acquisition. However, the brokerage remains cautious of potential weakness in services and volatility in the end markets for this year.

While we acknowledge the potential of Certara Inc. (NASDAQ:CERT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CERT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stock To Buy Now and Complete List of All AI Companies Under $2 Billion Market Cap.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9